`To:
`Cc:
`Subject:
`Date:
`
`Donovan, Bindu
`Swanson, Robert D. (WDC); JANS-ZYTIGA; Sidley Zytiga IPR Team
`White, Brandon (WDC); *Abiraterone; Beel, Bryan D. (POR)
`RE: IPR2016-01332 - Exhibit 2134
`Tuesday, April 04, 2017 9:40:30 AM
`
`Dear Brandon,
`
`The market data underlying Exhibit 2134 came from IMS DDD data and Symphony claims data, which are third-party
`sources that compile such data. We note that Mylan’s expert on commercial success, Mr. Hofmann, has also relied upon
`IMS data in his analysis (see Mylan Exhibit 1017 at page 33, citing IMS data) and Mylan has not deemed it necessary to
`produce the underlying IMS database.
`
`Best regards. Bindu
`
`BINDU DONOVAN
`Partner
`
`SIDLEY AUSTIN LLP
`+1 212 839 8742
`bdonovan@sidley.com
`
`
`From: Swanson, Robert D. (Perkins Coie) [mailto:RSwanson@perkinscoie.com]
`Sent: Friday, March 31, 2017 3:41 PM
`To: Donovan, Bindu; JANS-ZYTIGA; Sidley Zytiga IPR Team
`Cc: White, Brandon (Perkins Coie); Abiraterone@perkinscoie.com; Beel, Bryan D. (Perkins Coie)
`Subject: IPR2016-01332 - Exhibit 2134
`
`On behalf of Brandon White:
`
`Counsel for Janssen,
`
`Janssen has not produced any of the data allegedly underlying the information in at least Exhibit 2134. Please immediately
`produce all data that is a source for, or otherwise underlies, the information in Exhibit 2134.
`
`Best,
`Brandon White
`
`Robert Swanson | Perkins Coie LLP
`ASSOCIATE*
`700 Thirteenth Street, N.W. Suite 600
`Washington, DC 20005-3960
`D. +1.202.654.1729
`F. +1.202.654.9507
`E. RSwanson@perkinscoie.com
`
` *
`
` Admitted only in California
`** Admission to DC pending
`
`
`NOTICE: This communication may contain privileged or other confidential information. If you have received it in error, please advise the sender by reply email and
`immediately delete the message and any attachments without copying or disclosing the contents. Thank you.
`
`
`
`****************************************************************************************************
`
`This e-mail is sent by a law firm and may contain information that is privileged or confidential.
`If you are not the intended recipient, please delete the e-mail and any attachments and notify us
`immediately.
`
`****************************************************************************************************
`
`MYLAN PHARMS. INC. EXHIBIT 1150 PAGE 1
`
`